Editorial: the pitfalls of combination therapy.
作者信息
Vermersch Patrick
出版信息
Int MS J. 2006 Nov;13(3):75-6.
PMID:17101074
Abstract
摘要
相似文献
1
Editorial: the pitfalls of combination therapy.社论：联合治疗的陷阱
Int MS J. 2006 Nov;13(3):75-6.
2
Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.加拿大多发性硬化症临床诊所网络关于：多发性硬化症中疾病修正药物使用的共识声明。
Can J Neurol Sci. 1999 Nov;26(4):274-5. doi: 10.1017/s0317167100000378.
3
Interferon beta and glatiramer acetate therapy.干扰素β和醋酸格拉替雷治疗。
Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4.
4
Concomitant therapy for multiple sclerosis.多发性硬化症的联合治疗。
Neurology. 2004 Dec 14;63(11 Suppl 5):S28-34. doi: 10.1212/wnl.63.11_suppl_5.s28.
5
[Pharmacological treatment of multiple sclerosis].
Tidsskr Nor Laegeforen. 2010 Mar 11;130(5):490-2. doi: 10.4045/tidsskr.09.1126.
6
[Disease modifying drugs in multiple sclerosis and pregnancy].[多发性硬化症的疾病修饰药物与妊娠]
Med Clin (Barc). 2012 Sep 22;139(7):316-8. doi: 10.1016/j.medcli.2012.04.021. Epub 2012 Jun 27.
7
Multiple sclerosis disease-modifying therapy and pregnancy.多发性硬化症疾病修正治疗与妊娠
Mult Scler. 2016 May;22(6):715-6. doi: 10.1177/1352458516642316.
8
[Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].[治疗技术的后勤保障与描述（使用疾病修正药物——DMD的方案）]
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):93-8.
9
Multiple sclerosis: monotherapy rules.多发性硬化症：单一疗法规则
Ann Neurol. 2013 Mar;73(3):A5-6. doi: 10.1002/ana.23886.
10
Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.关于舒海巴尔等人的评论：免疫调节剂疗法对多发性硬化症骨密度的有利影响。
Ir J Med Sci. 2009 Jun;178(2):235-6; author reply 237-8. doi: 10.1007/s11845-009-0275-y. Epub 2009 Jan 31.
Zotero 插件